David R Gandara

18PUBLICATIONS
142CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 03, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

|Mar 11, 2026
Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

David R Gandara, Mahmut Gümüş, Saadettin Kilickap

|Jul 07, 2025
Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types".

Ryon P Graf, David R Gandara

|Jun 17, 2025
Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non-Small Cell Lung Cancer.

Jesse D Ortendahl, Gebra Cuyun Carter, Snehal G Thakkar

|Jun 04, 2025
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Philip C Mack, Mary W Redman, Hanna Tukachinsky

|Feb 06, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.

David R Gandara, Neeraj Agarwal, Shilpa Gupta

Pageof 3

Frequent Collaborators

6 joint publications

Mary W Redman

6 joint publications

Karen Kelly

4 joint publications

Philip C Mack

4 joint publications

Karen L Reckamp